Communicating prostate cancer risk: What should we be telling our patients?

Medical Journal of Australia

Volumn 182, Issue 9, 2005, Pages 472-475

  Baade, Peter D ^a   Steginga, Suzanne K ^a   Pinnock, Carole B ^b   Aitken, Joanne F ^a  

^a CANCER COUNCIL QUEENSLAND   (Australia)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; FAMILY HISTORY; HUMAN; MALE; MEDICAL DECISION MAKING; PATIENT EDUCATION; POPULATION RISK; PRACTICE GUIDELINE; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR;

EID: 18744388888     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb06790.x     Document Type: Article

References (33)

1. Wolf AM, Philbrick JT, Schorling JB. Predictors of interest in prostatespecific antigen screening and the impact of informed consent: what should we tell our patients? Am J Med 1997; 103: 308-314.
2. Gattellari M, Ward J. Does evidence-based information about screening for prostate cancer enhance consumer decision making? A randomised controlled trial. J Med Screen 2003; 10: 27-39.
3. Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ 2003; 327: 741-744.
4. Paling J. Strategies to help patients understand risks. BMJ 2003; 327: 745-748.
5. Frankel S, Smith GD, Donovan J, et al. Screening for prostate cancer. Lancet 2003; 361: 1122-1128.
6. Bunting PS. Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta 2002; 315: 71-97.
7. Prostate cancer screening: summary of the review prepared by the Australian Health Technology Advisory Committee. Canberra: Commonwealth Department of Health and Family Services, 2003. Available at: http://www7.health.gov.au/pubs/ahtac/prostate.htm (accessed Mar 2005).
8. Guidelines for preventive activities in general practice (Updated 5th edition). Aust Fam Physician 2002; (Special issue - May 2002).
9. The Cancer Council Australia. National cancer prevention policy 2004-06. Sydney: Cancer Council Australia, 2004. Available at: http://www.cancer.org.au/documents/NatCancerPreventPol_04-06.pdf (accessed Dec 2004).
10. Steginga SK, Pinnock C, Baade PD. The early detection of prostate cancer in general practice: supporting patient choice. Practice resource in supporting patients' choice about PSA testing in general practice. Brisbane: Queensland Cancer Fund, 2005.
11. Cancer in Australia 2001. Canberra: Australian Institute of Health and Welfare and Australasian Association of Cancer Registries, 2004. (AIHW Catalogue No. CAN 23.)
12. Australian Bureau of Statistics. Causes of death (various years). Canberra: ABS, 2004. (ABS Catalogue No. 3303.0.)
13. Grulich AE, Swerdlow A, dos Santos Silva I, et al. Is the apparent rise in cancer mortality in the elderly real? Analysis of changes in certification and coding of cause of death in England and Wales, 1970-1990. Int J Cancer 1995; 63: 164-168.
14. SAS OnlineDoc [computer program]. Version 9.1.2. Cary, NC: SAS Institute Inc, 2004.
15. Australian Bureau of Statistics. Life tables Australia 2001-2003. Canberra: ABS, 2004. (ABS Catalogue No. 3302.0.55.001.)
16. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003; 91: 789-794.
17. Parkin DM, Whelan SL, Ferlay J, et al, editors. Cancer incidence in five continents. Volume VIII. IARC Scientific Publications No 155. Lyon, France: International Agency for Research on Cancer (WHO) and International Association of Cancer Registries, 2002.
18. Condon JR, Armstrong BK, Barnes A, et al. Cancer in Indigenous Australians: a review. Cancer Causes Control 2003; 14: 109-121.
19. Clinical practice guidelines for the prevention, diagnosis and management of lung cancer. Sydney: The Cancer Council Australia, 2004.
20. Leach R, Pollock B, Basler J, et al. Chemoprevention of prostate cancer: focus on key opportunities and clinical trials. Urol Clin North Am 2003; 30: 227-237.
21. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859-864.
22. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101: 3-27.
23. DeMarzo AM, Nelson WG, Issacs WB, et al. Pathological and molecular aspects of prostate cancer. Lancet 2003; 361: 955-964.
24. Cancer survival in Australia 2001: Part 2 Statistical tables. Canberra: Australian Institute of Health and Welfare and Australasian Association of Cancer Registries, 2001. (AIHW Catalogue No. CAN 14.)
25. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713-2719.
26. Weller D, Pinnock C, Silagy C, et al. Prostate cancer testing in SA men: influence of sociodemographic factors, health beliefs and LUTS. Aust N Z J Public Health 1998; 22(3 Suppl): 400-402.
27. Ward JE, Hughes AM, Hirst GHL, et al. Men's estimate of prostate cancer risk and self-reported rates of screening. Med J Aust 1997; 167: 250-253.
28. Steginga SK, Occhipinti S, Gardiner RA, et al. Making decisions about treatment for localised prostate cancer. BJU Int 2002; 89: 255-260.
29. Pinnock CB. PSA testing in general practice: can we do more now [conference report]. Med J Aust 2004; 180: 379-381.
30. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379-385.
31. Klotz LH. Active surveillance with selective delayed intervention: a biologically nuanced approach to favorable-risk prostate cancer. Clin Prostate Cancer 2003; 2: 106-110.
32. Standaert B, Denis L. The European randomised study of screening for prostate cancer. Cancer 1997; 80: 1830-1834.
33. De Koning HJ, Auvinen A, Sanchez AB, et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002; 97: 237-244.